22 May 2015

Klaricid Paediatric (Clarithromycin) - United Kingdom

Klaricid Paediatric Suspension

Generic Matches for Clarithromycin (3)
Klaricid Adult Sachet
Klaricid XL tablets
Klaricid Paediatric Suspension 125mg/5ml

Last Updated on 22 May 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Klaricid Paediatric Suspension Indication

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Klaricid Paediatric Suspension 125mg/5ml is indicated in children 6 months to 12 years.

Klaricid Paediatric Suspension 125mg/5ml is indicated for the treatment of infections caused by susceptible organisms. Indications include:

Lower respiratory tract infections.

Upper respiratory tract infections.

Skin and skin structure infections.

Acute otitis media.

Klaricid Paediatric Suspension 125mg/5ml is usually active against the following organisms in vitro:

Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible); Streptococcus pyogenes (Group A beta-haemolytic streptococci); alpha-haemolytic streptococci (viridans group); Streptococcus (Diplococcus) pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.

Gram-negative Bacteria: Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae; Legionella pneumophila, Bordetella pertussis, Helicobacter pylori; Campylobacter jejuni.

Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.

Other Organisms: Chlamydia trachomatis; Mycobacterium avium; Mycobacterium leprae; Chlamydia pneumoniae.

Anaerobes: Macrolide-susceptible Bacteroides fragilis; Clostridium perfringens; Peptococcus species; Peptostreptococcus species; Propionibacterium acnes.

Klaricid Paediatric Suspension 125mg/5ml has bactericidal activity against several bacterial strains. These organisms include H. influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae, Helicobacter pylori and Campylobacter species.

The activity of clarithromycin against H. pylori is greater at neutral pH than at acid pH.

Klaricid Paediatric Suspension Generic Name




Summary Product Characteristics (SPCs) Links
All SPC - Klaricid Paediatric Suspension (external site)
SPC - Klaricid Paediatric Suspension 125mg/5ml (external site)
SPC - Klaricid Paediatric Suspension 250mg/5ml (external site)

Related Learning Zones

Anti-Infectives Knowledge Network CDI

Anti-Infectives Knowledge Network CDI

The Anti-Infectives Knowledge Network – Clostridium difficile infection (AIKN-CDI), an initiative by Astellas Pharma EMEA, shares the expertise and experience of thought leaders in the therapy area of anti-infectives, with a particular focus on C. difficile infection.

Recent updates include ECCMID, ICDS, EBMT and ISICEM 2015 slide decks and congress reports, an infographic on ‘CDI in the EU’, data from the largest ever European clinician consensus report, as well as congress overviews, news reports and CDI expert perspectives.

Anti-Infectives Knowledge Network IFI

Anti-Infectives Knowledge Network IFI

The Anti-Infectives Knowledge Network – Invasive Fungal Infections (AIKN-IFI), an initiative by Astellas Pharma EMEA, assembles the experience and expertise of a number of thought leaders in the area of anti-infectives, with a particular focus on invasive fungal infections.

This free resource is regularly updated with congress highlights, industry reports, policy changes, clinical guidelines and downloadable material from major medical events, so make sure you return often.

August 2015 MYC/15/0023/EUa

Klaricid Paediatric Marketing Information

Klaricid Paediatric Generic Name
Marketing Company
BGP Products Ltd.
Drug Type
Date of Issue, Marketing Authority - Klaricid Paediatric Suspension 125mg/5ml: 16/10/1995

- Klaricid Paediatric Suspension 250mg/5ml: 19/05/1999

Related Drugs - Infectious Diseases

Back to top